Jpmorgan Chase & CO Y M Abs Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 30,335 shares of YMAB stock, worth $319,730. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,335
Previous 27,481
10.39%
Holding current value
$319,730
Previous $331,000
20.24%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding YMAB
# of Institutions
107Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$43.1 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$31 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$23.1 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$21.5 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$19.3 Million0.15% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $461M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...